Economic Outcomes of Isavuconazole to Prevent Invasive Fungal Infection in Immunocompromised Adults: Initial Experience at an Academic Medical Center

BACKGROUND: Isavuconazole (ISA) is a once-daily, extended-spectrum triazole approved for treatment of invasive aspergillosis and mucormycosis. The pharmacokinetic profile, daily dosing, lack of therapeutic drug monitoring (TDM) and reduced cost make ISA a promising option for use as prophylaxis for...

Descripción completa

Detalles Bibliográficos
Autores principales: Kowalewska, Christina A, Tallman, Gregory B, Pham, Aaron N, Lewis, James S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630875/
http://dx.doi.org/10.1093/ofid/ofx163.1264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630875/
http://dx.doi.org/10.1093/ofid/ofx163.1264

Ejemplares similares